



US008183274B2

(12) **United States Patent**
Sawyers et al.

(10) **Patent No.:** **US 8,183,274 B2**
(45) **Date of Patent:** **May 22, 2012**

- (54) **TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS**
- (75) Inventors: **Charles L. Sawyers**, New York, NY (US); **Michael E. Jung**, Los Angeles, CA (US); **Charlie D. Chen**, Shanghai (CN); **Samedy Ouk**, Costa Mesa, CA (US); **Chris Tran**, New York, NY (US); **John Wongvipat**, Nanuet, NY (US)
- (73) Assignee: **The Regents of the University of California**, Oakland, CA (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **12/708,523**
(22) Filed: **Feb. 18, 2010**

(65) **Prior Publication Data**
US 2010/0172975 A1 Jul. 8, 2010

Related U.S. Application Data
(62) Division of application No. 11/433,829, filed on May 15, 2006, now Pat. No. 7,709,517.
(60) Provisional application No. 60/680,835, filed on May 13, 2005, provisional application No. 60/750,351, filed on Dec. 15, 2005, provisional application No. 60/756,552, filed on Jan. 6, 2006, provisional application No. 60/786,837, filed on Mar. 29, 2006.

(51) **Int. Cl.**
A61K 31/4166 (2006.01)
A61K 31/4184 (2006.01)
C07D 233/86 (2006.01)
(52) **U.S. Cl.** **514/391; 548/321.1; 548/301.4**
(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**
U.S. PATENT DOCUMENTS
3,823,240 A 7/1974 Sauli
379,038 A 1/1975 Magnani
3,923,994 A 12/1975 Magnani
3,984,430 A 10/1976 Curran
4,097,578 A 6/1978 Perronnet et al.
4,234,736 A 11/1980 Bernauer et al.
4,304,782 A 12/1981 Dumont et al.
4,312,881 A 1/1982 Wootton
4,399,216 A 8/1983 Axel et al.
4,407,814 A 10/1983 Bernauer et al.
4,427,438 A 1/1984 Nagano et al.
4,473,393 A 9/1984 Nagpal
4,482,739 A 11/1984 Bernauer et al.
4,559,157 A 12/1985 Smith et al.
4,608,392 A 8/1986 Jacquet et al.
4,749,403 A 6/1988 Liebl et al.
4,753,957 A 6/1988 Chan
4,820,508 A 4/1989 Wortzman
4,859,228 A 8/1989 Prisbylla
4,873,256 A 10/1989 Coussediere et al.

4,938,949 A	7/1990	Borch et al.
4,944,791 A	7/1990	Schroder et al.
4,992,478 A	2/1991	Geria
5,010,182 A	4/1991	Brake et al.
5,069,711 A	12/1991	Fischer et al.
5,071,773 A	12/1991	Evans et al.
5,084,472 A	1/1992	Moguilewsky et al.
5,166,358 A	11/1992	Seuron et al.
5,411,981 A	5/1995	Gaillard-Kelly et al.
5,434,176 A	7/1995	Claussner et al.
5,554,607 A	9/1996	Elokda et al.
5,556,983 A	9/1996	Claussner et al.
5,589,497 A	12/1996	Claussner et al.
5,614,620 A	3/1997	Liao et al.
5,627,201 A	5/1997	Gaillard-Kelly et al.
5,646,172 A	7/1997	Claussner et al.
5,656,651 A	8/1997	Sovak et al.
5,705,654 A	1/1998	Claussner et al.
5,726,061 A	3/1998	Robbins et al.
5,750,553 A	5/1998	Claussner et al.
5,783,707 A	7/1998	Elokda et al.
RE35,956 E	11/1998	Gaillard-Kelly et al.
5,958,936 A	9/1999	Claussner et al.
5,985,868 A	11/1999	Gray
6,087,509 A	7/2000	Claussner et al.
6,107,488 A	8/2000	Bouchet et al.
6,172,076 B1	1/2001	Embrey et al.
6,235,910 B1	5/2001	Beller et al.
6,242,611 B1	6/2001	Claussner et al.
6,307,030 B1	10/2001	French et al.
6,350,763 B1	2/2002	Kelly et al.
6,472,415 B1	10/2002	Sovak et al.
6,479,063 B2	11/2002	Weisman et al.

(Continued)

FOREIGN PATENT DOCUMENTS

AU 217893 6/1958

(Continued)

OTHER PUBLICATIONS

Scher, et al., *Lancet* 375:9724 (2010).*

Jung, et al., *J. Med. Chem.* 53:2779 (2010).*

Schafer et al., *Drug Discovery Today*, 13:913 (2008).*

Horig et al., *Journal of Translational Medicine*, 2:44 (2004).*

A Textbook of Drug Design and Development, P. Krosggaard-Larson and H. Bundgaard, eds. Ch 5, pp. 113-191 (Harwood Academic Publishers, 1991).

A.M. Soto et al. Control of Cell Proliferation: Evidence for Negative Control on Estrogen-sensitive T47D Human Breast Cancer Cells., *Cancer Research*, 46, (1986), pp. 2271-2275.

Abstract submitted by Samedy Ouk, Prostate Cancer Foundation Scientific Retreat, Scottsdale, Arizona, Sep. 29-Oct. 1, 2005.

Ausubel et al., *Current Protocols in Molecular Biology*, Wiley Interscience Publishers, (1995).

Baek, S.H. et al. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. *Cell* 110, 55-67 (2002).

Balk, S.P. Androgen receptor as a target in androgen-independent prostate cancer. *Urology* 60, 132-8; discussion 138-9 (2002).

(Continued)

Primary Examiner — Yong Chu
Assistant Examiner — Michael Barker
(74) *Attorney, Agent, or Firm* — Venable LLP; Michael A. Gollin; Lars H. Genieser

(57) **ABSTRACT**

The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.

40 Claims, 29 Drawing Sheets



U.S. PATENT DOCUMENTS

6,489,163	B1	12/2002	Roy et al.	
6,506,607	B1	1/2003	Shyjan	
6,828,471	B2	12/2004	Sawyers et al.	
6,949,521	B2	9/2005	Chu et al.	
7,138,421	B2	11/2006	Cleve et al.	
7,271,188	B2	9/2007	Tachibana et al.	
7,601,748	B2	10/2009	Cleve et al.	
7,709,517	B2 *	5/2010	Sawyers et al.	514/392
7,718,684	B2	5/2010	Jung et al.	
8,110,594	B2	2/2012	Jung et al.	
2002/0133833	A1	9/2002	Sawyers et al.	
2003/0225138	A1	12/2003	Sircar et al.	
2004/0009969	A1	1/2004	Cleve et al.	
2004/0116417	A1	6/2004	Boubia et al.	
2005/0153968	A1	7/2005	Bi et al.	
2006/0127902	A1	6/2006	Madden et al.	
2007/0166717	A1	7/2007	Sawyer et al.	
2007/0249697	A1	10/2007	Tachibana et al.	
2007/0254933	A1 *	11/2007	Jung et al.	514/387
2008/0139634	A2	6/2008	Jung et al.	
2009/0111864	A1	4/2009	Jung et al.	
2010/0172975	A1	7/2010	Sawyers et al.	
2010/0210665	A1 *	8/2010	Sawyers et al.	514/254.05

FOREIGN PATENT DOCUMENTS

DE	2102605	A1	7/1971
DE	2126187		12/1971
DE	26 14 831	A1	10/1977
EP	0 001 813	A1	5/1979
EP	0002259	A2	6/1979
EP	0017976	A2	10/1980
EP	0017976	A2	10/1980
EP	0017976	B1	10/1980
EP	0017976	A3	4/1981
EP	0 091 596	A2	10/1983
EP	0 091 596	A3	11/1984
EP	0144098	A1	6/1985
EP	0331232	A2	9/1989
EP	362179	A2	4/1990
EP	0 436 426	A1	7/1991
EP	0494819	A1	7/1992
EP	0572191	A1	12/1993
EP	0578516	A1	1/1994
EP	0580459	A1	1/1994
EP	0721944	A1	7/1996
EP	0770613	A1	5/1997
EP	1790640	A1	5/2007
FR	2 075 751		10/1971
FR	2 329 276		5/1977
FR	2693461	A1	1/1994
FR	2715402	A1	7/1995
FR	2845384	A1	4/2004
JP	48 87030		11/1973
JP	59-210083		11/1984
JP	59210083	A	11/1984
JP	1009978		1/1989
JP	1009978	A	1/1989
JP	2019363	A	1/1990
JP	38 45455	B2	11/2006
WO	WO-9013646	A1	11/1990
WO	WO-95/18794	A1	7/1995
WO	WO-9700071	A1	1/1997
WO	WO-9719064	A1	5/1997
WO	WO-9719931	A1	6/1997
WO	WO-0017163	A1	3/2000
WO	WO-00/26195	A1	5/2000
WO	WO-00/44731	A1	8/2000
WO	WO-01/07048	A1	2/2001
WO	WO-01/92253	A2	12/2001
WO	WO-01/94346	A1	12/2001
WO	WO-02053155	A1	7/2002
WO	WO-02081453	A1	10/2002
WO	WO-03/032994	A2	4/2003
WO	WO-03029245	A1	4/2003
WO	WO-03057220	A1	7/2003
WO	WO-03093243	A1	11/2003
WO	WO-03096980	A2	11/2003

WO	WO-2004/022572	A1	3/2004
WO	WO-2004031160	A2	4/2004
WO	WO-2004070050	A2	8/2004
WO	WO-2004/111031	A1	12/2004
WO	WO-2005/042488	A1	5/2005
WO	WO-2005059109	A2	6/2005
WO	WO-2005060661	A2	7/2005
WO	WO-2005/089752	A2	9/2005
WO	WO-2005089752	A2	9/2005
WO	WO-2005099693	A2	10/2005
WO	WO-2006/010642	A1	2/2006
WO	WO-2006010642	A1	2/2006
WO	WO-2006028226	A1	3/2006
WO	WO-2005/059109	A3	8/2006
WO	WO-2006124118	A1	11/2006
WO	WO-2007/045877	A1	4/2007
WO	WO-2007126765	A2	11/2007
WO	WO-2007127010	A2	11/2007
WO	WO-2008119015	A2	10/2008
WO	WO-2009/055053	A2	4/2009
WO	WO-2009/076408	A2	6/2009
WO	WO 2009/076408	A3	7/2009

OTHER PUBLICATIONS

- Batch,J.A., et al., "Androgen receptor gene mutations identified by SSCP in fourteen subjects with androgen insensitivity syndrome", *Hum. Mol. Genet.* 1 (7), 497-503 (1992).
- Bohl et al., "Structural basis for antagonism and resistance of bicalutamide in prostate cancer", *Proc. Nat. Acad. Sci.*, 2005, v. 102(17), pp. 6201-6206.
- Brockschmidt,F.F., et al., "The two most common alleles of the coding GGN repeat in the androgen receptor gene cause differences in protein function", *J. Mol. Endocrinol.* 39 (1), 1-8 (2007).
- Burnstein et al. Androgen Glucocorticoid Regulation of Androgen Receptor cDNA Expression. *Molecular and Cellular Endocrinology.* 1995. v. 115, pp. 177-186.
- Cai,C., et al., "c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer", *Mol. Cancer Res.* 5 (7), 725-735 (2007).
- Chang et al., *Science* 240 (4850), 324-326 (1988).
- Chen, C.D. et al., "Molecular determinants of resistance to antiandrogen therapy", *Nature Medicine*, vol. 10, No. 1 (Jan. 2004) pp. 33-39.
- Cinar et al. Androgen Receptor Mediates the Reduced Tumor Growth, Enhanced Androgen Responsiveness, and Selected Target Gene Transactivation in Human Prostate Cancer Cell Line. *Cancer Research.* 2001. v. 61, pp. 7310-7317.
- Cousty-Berlin, et al., "Preliminary Pharmacokinetics and Metabolism of Novel Non-steroidal Antiandrogens in the Rat: Relation of their Systemic Activity to the Formation of a Common Metabolite," *J. Steroid Biochem. Molec. Biol.*, vol. 51, No. 1/2, pp. 47-55 (1994).
- Craft, N. et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. *Cancer Res* 59,5030-6 (1999).
- Craft, N., Shostak, Y., Carey, M. & Sawyers, C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. *Nat Med* 5, 280-5 (1999).
- Creaven, P.J. et al., "Pharmacokinetics and Metabolism of Nilutamide", *Supp. Urology*, vol. 37, No. 2 (Feb. 1991) pp. 13-19.
- Data Sheet from U.S. Patent and Trademark Office (USPTO) File Wrapper for U.S. Appl. No. 08/807,760, (2009).
- DePrimo, S.E. et al. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. *Genome Biol* 3, RESEARCH0032 (2002).
- Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985).
- Edwards, J., Krishna, N. S., Grigor, K.M. & Bartlett, J.M. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. *Br J Cancer* 89, 552-6 (2003).
- Ellis, W.J. et al. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. *Clin Cancer Res* 2, 1039-48 (1996).

- Ellwood-Yen, K. et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. *Cancer Cell* 4, 223-38 (2003).
- Extended European Search Report issued in European Patent Application No. EP 06748863.5, mailed on Feb. 12, 2009.
- Feher, et al., "BHB: A Simple Knowledge-Based Scoring Function to Improve the Efficiency of Database Screening," *J. Chem. Inf. Comput. Sci.*, vol. 43, pp. 1316-1327 (2003).
- Feldman, B.J. & Feldman, D. The development of androgen-independent prostate cancer. *Nat Rev Cancer* 1, 34-45 (2001).
- Font de Mora, J. & Brown, M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. *Mol Cell Biol* 20, 5041-7 (2000).
- Foury, et al., "Control of the Proliferation of Prostate Cancer Cells by an Androgen and Two Antiandrogens. Cell Specific Sets of Responses," *J. Steroid Biochem. Molec. Biol.*, vol. 66, No. 4, pp. 235-240 (1998).
- Gelmann, E.P. Molecular biology of the androgen receptor. *J Clin Oncol* 20, 3001-15 (2002).
- Gioeli, D. et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. *J Biol Chem* 277, 29304-14 (2002).
- Glass, C.K. & Rosenfeld, M.G. The coregulator exchange in transcriptional functions of nuclear receptors. *Genes Dev* 14, 121-41 (2000).
- Goubet, et al., Conversion of a Thiohydantoin to the Corresponding Hydantoin via a Ring-Opening/Ring Closure Mechanism, *Tetrahedron Letters*, vol. 37, No. 43, pp. 7727-7730 (1996).
- Grad, J.M., Dai, J.L., Wu, S. & Burnstein, K.L. Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. *Mol Endocrinol* 13, 1896-911 (1999).
- Graham and van der Eb, "A new technique for the assay of infectivity of human adenovirus 5 DNA", *Virology*, v. 52(2) (Apr. 1973) pp. 456-467.
- Gregory, C.W. et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. *Cancer Res* 61, 4315-9 (2001).
- Gregory, C.W., Johnson, R.T., Jr., Mohler, J.L., French, F.S. & Wilson, E.M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. *Cancer Res* 61, 2892-8. (2001).
- Hamilton-Reeves, J.M., et al., "Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-beta expression or serum hormonal profiles in men at high risk of prostate cancer", *J. Nutr.* 137 (7), 1769-1775 (2007).
- Holzbeierlein, J. et al., "Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance", *Am. J. Pathology*, vol. 164, No. 1 (Jan. 2004) pp. 217-227.
- Homma, S., et al., "Differential levels of human leukocyte antigen-class I, multidrug-resistance 1 and androgen receptor expressions in untreated prostate cancer cells: the robustness of prostate cancer", *Oncol. Rep.* 18 (2), 343-346 (2007).
- Horszewicz, J.S. et al. LNCaP model of human prostatic carcinoma. *Cancer Res* 43, 1809-18 (1983).
- Huang, Z.Q., Li, J. & Wong, J. AR possess an intrinsic hormone-independent transcriptional activity. *Mol Endocrinol* 16, 924-37 (2002).
- International Search Report issued in International Application No. PCT/US2007/007854, mailed on Apr. 15, 2008.
- International Search Report issued in International Application No. PCT/US2008/012149 mailed on Apr. 29, 2009.
- International Search Report issued in PCT Application No. PCT/US06/11417 dated Jul. 3, 2006.
- International Search Report issued in PCT Application PCT/US2004/042221, mailed on Jun. 20, 2005.
- International Search Report issued in PCT Application PCT/US2005/005529, mailed on Nov. 10, 2005.
- International Search Report issued in PCT Application PCT/US2007/07485, mailed on Sep. 4, 2008.
- Jones, Genetics, 85: 23 (1977).
- Karp et al., "Prostate Cancer Prevention: Investigational Approaches and Opportunities", *Cancer Res.*, v. 56 (Dec. 15, 1996) pp. 5547-5556.
- Karvonen, et al., "Interaction of Androgen Receptors with Androgen Response Element in Intact Cells," *The Journal of Biological Chemistry*, vol. 272, No. 25, pp. 15973-15979 (1997).
- Kato, S. et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. *Science* 270, 1491-4 (1995).
- Kempainen, et al., "Distinguishing Androgen Receptor Agonists and Antagonists: Distinct Mechanisms of Activation by Medroxyprogesterone Acetate and Dihydrotestosterone," *Mol. Endocrinol.*, vol. 13, pp. 440-454 (1999); mend.endojournals.org.
- Keown et al., *Methods in Enzymology*, 185:527-537 (1990).
- Kingsman et al., *Gene*, 7: 141 (1979).
- Kinoshita, H. et al. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. *Cancer Res* 60, 3623-30 (2000).
- Klein, K.A. et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. *Nat Med* 3, 402-8 (1997).
- Kousteni, S. et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. *Cell* 104, 719-30 (2001).
- Laitinen, S., Karhu, R., Sawyers, C.L., Vessella, R.L. & Visakorpi, T. Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization. *Genes Chromosomes Cancer* 35, 66-73 (2002).
- Li, P. et al. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. *Am J Pathol* 161, 1467-74 (2002).
- Linja, M.J. et al., Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer, *Cancer Research*, vol. 61 (May 1, 2001) pp. 3550-3555.
- Lobaccaro, J.M. et al. Molecular modeling and in vitro investigations of the human androgen receptor DNA-binding domain: application for the study of two mutations. *Mol Cell Endocrinol* 116, 137-47 (1996).
- Lu et al. "Molecular Mechanisms of Androgen-Independent Growth of Human Prostate Cancer LNCaP-AI Cells", *Endocrinology* 1999, vol. 140, No. 11, pp. 5054-5059.
- Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1991).
- Manolagas, S.C., Kousteni, S. & Jilka, R.L. Sex steroids and bone. *Recent Prog Horm Res* 57, 385-409 (2002).
- Mansour et al., *Nature*, 336:348-352 (1988).
- Marhefka, et al., "Homology Modeling Using Multiple Molecular Dynamics Simulations and Docking Studies of the Human Androgen Receptor Ligand Binding Domain Bound to Testosterone and Nonsteroidal Ligands," *J. Med. Chem.*, vol. 44, No. 11, pp. 1729-1740 (2001).
- Masiello, D., Cheng, S., Buble, G.J., Lu, M.L. & Balk, S.P. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. *J Biol Chem* 277, 26321-6 (2002).
- Matias, et al., "Local Inhibition of Sebaceous Gland Growth by Topically Applied RU 58841," *NY Acad. Sci.*, vol. 761, pp. 56-65 (1995).
- Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. *J Med Chem* 45, 1439-46 (2002).
- Matias, P.M. et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. *J Biol Chem* 275, 26164-71 (2000).
- McDonnell, T.J. et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. *Cancer Res* 52, 6940-4 (1992).
- Migliaccio, A. et al. Steroid-induced androgen receptor-oestradial receptor beta-*Src* complex triggers prostate cancer cell proliferation. *Embo J* 19, 5406-17 (2000).
- Muller et al., 1991, *Mol. & Cell. Bio.* 11:1785.

- Nam et al., "Action of the Src Family Kinase Inhibitor, Dasatinib (BMS-354825), on Human Prostate Cancer Cells", *Cancer Res.*, 2005, v. 65(20), pp. 9185-9189.
- Navone, N. M., et al., "Model Systems of Prostate Cancer: Uses and Limitations" *Cancer Metastasis*, Kluwer Academic Publishers, Dordrecht, NL, 17 (4), 1999, pp. 361-371.
- NM_000044<[http://www.ncbi.nlm.nih.gov:80/entrez/viewer.fcgi?cmd=Retrieve&db=nucleotide&list_uids=21322251](http://www.ncbi.nlm.nih.gov:80/entrez/viewer.fcgi?cmd=Retrieve&db=nucleotide&list_uids=21322251&dopt=GenBank)&dopt=GenBank
- &term=sapiens+AR+androgen+receptor+prostate+cancer &qty=1>gi:21322251, printed Oct. 24, 2007.
- Norris, J.D. et al. Peptide antagonists of the human estrogen receptor. *Science* 285, 744-6 (1999).
- Notice of References Cited from U.S. Patent and Trademark Office (USPTO) File Wrapper for U.S. Appl. No. 08/807,760, 2009.
- Notice of References Cited of Jul. 24, 1992 from U.S. Patent and Trademark Office for U.S. Appl. No. 07/819,110, 2009.
- Office Action (paper No. 10) from U.S. Patent and Trademark Office for U.S. Appl. No. 08/064,257, 2009.
- Office Action (paper No. 7) from U.S. Patent and Trademark Office for U.S. Appl. No. 08/064,257, 2009.
- Office Action in U.S. Appl. No. 10/583,280 mailed on Nov. 29, 2010.
- Office Action in U.S. Appl. No. 11/730,168 mailed on Oct. 8, 2010.
- Office Action in U.S. Appl. No. 12/257,743 mailed on Nov. 20, 2009.
- Office Action issued in U.S. Appl. No. 10/590,445, mailed on Mar. 2, 2009.
- Office Action of Jan. 18, 1994 from U.S. Patent and Trademark Office for U.S. Appl. No. 08/064,257.
- Office Action of Feb. 22, 1993 from U.S. Patent and Trademark Office for U.S. Appl. No. 07/819,110.
- Office Action of Jun. 1, 1994 from U.S. Patent and Trademark Office for U.S. Appl. No. 07/819,110.
- Office Action of Jul. 23, 2008 from U.S. Patent and Trademark Office for U.S. Appl. No. 10/590,445.
- Office Action of Aug. 11, 2009 from U.S. Patent and Trademark Office for U.S. Appl. No. 10/583,280.
- Office Action of Aug. 14, 1992 from U.S. Patent and Trademark Office for U.S. Appl. No. 07/819,110.
- Office Action of Sep. 2, 1993 from U.S. Patent and Trademark Office for U.S. Appl. No. 07/819,110.
- Ouk, S. et al., "Development of Androgen Receptor Inhibitors for Hormone-refractory Prostate Cancer", Prostate Cancer Foundation Meeting, Scottsdale, AZ, Sep. 29-Oct. 1, 2005.
- Perou, C.M. et al. Molecular portraits of human breast tumors. *Nature* 406, 747-52 (2000).
- Presentation of Charles Sawyers, Prostate Cancer Foundation Scientific Retreat, Scottsdale, Arizona, Sep. 29-Oct. 1, 2005.; C141.
- Raffo et al. Overexpression of bcl-2 Protects Prostate Cancer Cells from Apoptosis in Vitro and Confers Resistance to Androgen Depletion in Vivo. *Cancer Research*. 1995, v. 55. 4438-4445.
- Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro (ed.) 1995, Mack Publishing Company, Easton, PA.
- Sack, J.S. et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. *Proc Natl Acad Sci U S A* 98, 4904-9 (2001).
- Sambrook et al., *Molecular Cloning: A Laboratory Manual* 2nd edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
- Saunders, P.T., et al., "Point mutations detected in the androgen receptor gene of three men with partial androgen insensitivity syndrome", *Clin. Endocrinol. (Oxf)* 37 (3), 214-220 (1992).
- Schellhammer, P.F. et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. *J Urol* 157, 1731-5 (1997).
- Scher et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. *Lancet*. 375:1437 (cited as p. 9724 in Oct. 8, 2010 Office Action for U.S. Appl. No. 11/730,168 and Oct. 1, 2010 Office Action for U.S. Appl. No. 12/708,523).
- Sderholm, et al., "Three-Dimensional Structure—Activity Relationships of Nonsteroidal Ligands in Complex with Androgen Receptor Ligand-Binding Domain," *J. Med. Chem.*, vol. 48, No. 4, pp. 917-925 (2005).
- Shang, Y. & Brown, M. Molecular determinants for the tissue specificity of SERMs. *Science* 295, 2465-8 (2002).
- Shang, Y., Myers, M. & Brown, M. Formation of the androgen receptor transcription complex. *Mol Cell* 9, 601-10 (2002).
- Shi, Xu-Bao, et al., Functional analysis of 44 mutant androgen receptors from human prostate cancer. *Cancer Research* 62 (5), pp. 1496-1502 (Mar. 1, 2002).
- Shiau, A.K. et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. *Cell* 95, 927-37 (1998).
- Singh et al., "Androgen Receptor Antagonists (Antiandrogens): Structure-Activity Relationships", *Current Medicinal Chemistry*, 2000, 7, pp. 211-247.
- Sperry, et al., Androgen binding profiles of two distinct nuclear androgen receptors in Atlantic croaker (*Micropogonias undulatus*), *Journal of Steroid Biochemistry & Molecular Biology*, vol. 73, pp. 93-103 (2000).
- Stinchcomb et al., *Nature*, 282:39 (1979).
- Su, Q.R., et al., "Polymorphisms of androgen receptor gene in childhood and adolescent males with first-onset major depressive disorder and association with related symptomatology", *Int. J. Neurosci.* 117 (7), 903-917 (2007).
- Sweet, C.R., et al., "A unique point mutation in the androgen receptor gene in a family with complete androgen insensitivity syndrome", *Fertil. Steril.* 58 (4), 703-707 (1992).
- Szelei et al. Androgen-Induced Inhibition of Proliferation in Human Breast Cancer MCF7 Cells Transfected with Androgen Receptor. *Endocrinology*. 1997, v. 138 (4), pp. 1406-1412.
- Taplin, M.E. et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. *J Clin Oncol* 21, 2673-8 (2003).
- Taplin, M.E. et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. *N. Engl J Med* 332, 1393-8 (1995).
- Taplin, M.E. et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. *Cancer Res* 59, 2511-5 (1999).
- Teutsch, G.; Goubet, F.; Battmann, T.; Bonfils, A.; Bouchoux, F.; Cerede, E.; Gofflo, D.; Gaillard-Kelly, M.; Philibert, D. *J. Steroid Biochem. Molec. Biol.* 1994, 48, 111-119.
- The Pharmacological Basis of Therapeutics*, Goodman and Gilman, eds., Macmillan Publishing Co., New York, 1980.
- The Practice of Medicinal Chemistry*, Camille G. Wermuth et al., Ch 31, (Academic Press, 1996).
- Tremblay, A., Tremblay, G.B., Labrie, F. & Giguere, V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. *Mol Cell* 3, 513-9 (1999).
- Tschumper et al., *Gene*, 10: 157 (1980).
- Urlaub et al., *Proc. Natl. Acad. Sci. USA*, 77:4216 (1980).
- Van Dort, M. E.; Robins, D. M.; Wayburn, B. *J. Med. Chem.* 2000, 43, 3344-3347.
- Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. *Biochem Biophys Res Commun* 173, 534-40 (1990).
- Visakorpi, T. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. *Nat Genet* 9, 401-6 (1995).
- Wainstein, M.A. et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. *Cancer Res* 54, 6049-52 (1994).
- Wallen et al., "Androgen Receptor Gene Mutations in Hormone-Refractory Prostate Cancer", *J. Pathology* 1999, vol. 189, pp. 559-563.
- Wang, Long G., et al., "Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line", *Cancer Research* 61 (20), pp. 7544-7551 (Oct. 15, 2001).

- Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. *Cancer Cell* 4, 209-21 (2003).
- Wooster, R., et al., "A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenshein syndrome", *Nat. Genet.* 2 (2), 132-134 (1992).
- Written Opinion issued in International Application No. PCT/US2007/007854, mailed on Apr. 15, 2008.
- Written Opinion issued in International Application No. PCT/US2008/012149, mailed on Apr. 29, 2009.
- Written Opinion issued in PCT Application No. PCT/US2004/042221, mailed on Jun. 20, 2005.
- Written Opinion issued in PCT Application No. PCT/US2005/005529, mailed on Nov. 10, 2005.
- Written Opinion issued in PCT Application No. PCT/US2006/011417, mailed on Jul. 3, 2006.
- Written Opinion issued in PCT Application PCT/US2007/07485, mailed on Sep. 4, 2008.
- Zajchowski et al. Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. *1993. Cancer Research.* 53:5004-5011.
- Zarghami, et al., "Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer," *British Journal of Cancer*, vol. 75, No. 4, pp. 579-588 (1997).
- Zhou, H.Y. et al. Androgen-repressed phenotype in human prostate cancer. *Proc Natl Acad Sci U S A* 93,15152-7 (1996).
- Zhou, Z.X., Sar, M., Simental, J.A., Lane, M.V. & Wilson, E.M. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH₂-terminal and carboxyl-terminal sequences. *J Biol Chem* 269, 13115-23 (1994).
- Zoppi, S., et al. "Amino acid substitutions in the DNA-binding domain of the human androgen receptor are a frequent cause of receptor-binding positive androgen resistance", *Mol. Endocrinol.* 6 (3), 409-415 (1992).
- Listing of Chemical Abstracts search presented by with Oct. 8, 2010 Office Action for U.S. Appl. No. 11/730,168.
- Database CA, Chemical Abstracts Service (1994), Summary of Dhal P.N., *J Indian Chem Soc* 50 (1973) 680-684.
- Elokda et al. 2004, Design, synthesis, and biological evaluation of thio-containing compounds with serum HDL-cholesterol-elevating properties. *J Med Chem.* 47: 681-695.
- International Search Report issued in PCT Application PCT/US96/10286 on Oct. 4, 1996.
- Nakajima et al., 2002, Activated dimethyl sulfoxide dehydration of amide and its application to one-pot preparation of benzyl-type prefluoroimides. *Tetrahedron.* 58: 3561-3577.
- Notice of Allowance issued in U.S. Appl. No. 11/730,168 dated Jun. 10, 2011.
- Notice of Allowance issued in U.S. Appl. No. 10/583,280 dated Jun. 9, 2011.
- Notice of Allowance issued in U.S. Appl. No. 11/433,829 dated Jun. 8, 2009.
- Notice of Allowance issued in U.S. Appl. No. 11/433,829 dated Nov. 18, 2009.
- Office Action issued in U.S. Appl. No. 10/583,280 mailed on Apr. 2, 2010.
- Office Action issued in U.S. Appl. No. 11/433,829 mailed on Jan. 27, 2009.
- Office Action issued in U.S. Appl. No. 12/257,743 dated Jun. 29, 2010.
- Rao et al., 1988, Merits and considerations in the use of anti-androgen, *J. Steroid Biochem.* 31(48): 731-737.
- Raynaud et al., 1979, Action of a non-steroid anti-androgen, RU 23908, in peripheral and central tissues, *Journal of Steroid Biochemistry*, 11: 93-99.
- Restriction Requirement issued in U.S. Appl. No. 10/583,280 mailed on Aug. 11, 2009.
- Restriction Requirement Issued in U.S. Appl. No. 10/590,445 mailed on Jun. 5, 2008.
- Restriction Requirement Issued in U.S. Appl. No. 10/590,445 mailed on Mar. 26, 2008.
- Restriction Requirement Issued in U.S. Appl. No. 11/433,829 mailed on Nov. 3, 2008.
- Restriction Requirement issued in U.S. Appl. No. 12/257,743 mailed on Jul. 6, 2009.
- Supplementary European Search Report issued in EP 07754060 mailed on Oct. 11, 2010.
- Espada et al., "N₃-Arylspiroimidazolidine-2,4-Diones, N₃-Arylspiroimidazolidine-2-Thio-4-ones and 4-Hydroxy Derivatives. Synthesis and Anthelmintic Activity," *IL FARMACO*, vol. 45, No. 11, pp. 1237-1243 & title page (1990).
- Mancheva et al., "Preparation and Characterization of Diphenylindenonylthiohydantoin Derivatives of Non-Protein Cycloaliphatic Amino Acids," *Dokladi na Bulgarskata Akademiya na Naukite (Comptes rendu de l'Academie bulgare des Sciences)*, vol. 45, No. 11, pp. 67-70 & title page (1992).
- Ametamey et al., "Reaktionen von 3-(Dimethylamino)-2H-azirinen mit 1,3-Benzoxazol-2(3H)-thion," *Helvetica Chimica Acta*, vol. 73, No. 3, pp. 599-607 & title page (1990).
- Hough, "Synthesis of Imidazolin-2-ones by Rearrangement of N-Carbamoyliminium Salts Derived From 4-Hydroxyimidazolidin-2-ones," *Journal of Heterocyclic Chemistry*, vol. 26, No. 6, pp. 1523-1525 & title page (1989).
- Günzl et al., "Zur Chemie der vicinalen Triketone, XIII, Versuche zur Darstellung von Schiff'schen Basen aus cyclischen, vicinalen Triketonen," *Monatshefte für Chemie*, vol. 113, No. 11, pp. 1299-1310 & title page (1982).
- Crooks et al., "The Structure of Some Reaction Products of 2,3-Dihydrophenalene-1,2,3-Trione with Urea and its Homologues," *Gazzetta Chimica Italiana*, vol. 107, No. 5-6, pp. 353-354 & title page (1977).
- Dyer et al., "Preparation of Polyhydrouacils and Polyiminoimidazolidinones," *Journal of Polymer Science, Part A-1*, vol. 7, pp. 833-849 & title page (1969).
- Umezawa et al., "The Synthesis of Cyclic α -Amino Acids," *Bulletin of the Chemical Society of Japan*, vol. 40, No. 1, pp. 209-214 & title page (1967).
- Oldfield et al., "The Chemistry and Pharmacology of a Series of Cycloalkanespiro-5'-hydantoins," *Journal of Medical Chemistry*, vol. 8, No. 2, pp. 239-249 (1965).
- Nicole et al., "Synthèses D'Acides Aminés Cycliques À Partir de Dérivés de L'Acide Adipique," *Canadian Journal of Chemistry*, vol. 40, pp. 353-366 (1962).
- Chemical Abstracts, vol. 114, p. 185368 (May 13, 1991).
- Krüger et al., "Synthese und Reaktionen von 1-(1-Cyanoalkyl)-1-hydroxyharnstoff," *Arch. Pharm. (Weinheim)*, vol. 311, pp. 39-47 (1978).
- Dhal et al., "Synthesis of Thiohydantoins, Thiazolidones and Their Derivatives from N-(4'-Aryl Thiazole 2'-YL) Thioureas," *J. Indian Chem. Soc.*, vol. L, pp. 680-684 (Oct. 1973).
- Singh, "Amidine: Structure, Reactivity and Complexation Behaviour," *Int'l J. of Chem. Tech. Res.*, vol. 1(2), pp. 250-264 (2009).
- Aly et al., "Functionality of amidines and amidrazones," *ARKIVOC* (i), pp. 153-194 (2008).
- Office Action of Nov. 14, 2011 from U.S. Pat. & Trademark Office for U.S. Appl. No. 12/708,531.
- Chemical Abstracts Search provided with Oct. 8, 2010 Office Action in U.S. Appl. No. 11/730,168.
- Notice of Allowance issued in U.S. Appl. No. 11/730,168 mailed Sep. 20, 2011.
- Corrected Notice of Allowability issued in U.S. Appl. No. 11/730,168 mailed Dec. 22, 2011.
- Corrected Notice of Allowability issued in U.S. Appl. No. 11/730,168 mailed Jan. 19, 2012.
- Rao et al., "Merits and Considerations in the Use of Anti-Androgen," *J. Steroid Biochem.* 31 (4B), pp. 731-737 (1988).
- European Search Report dated Jul. 20, 2011 for European Application No. 07754060.7, 7 pages.
- Extended European Search Report dated Aug. 8, 2011 (search completed Jul. 12, 2011) for European Application No. 11163948.0, 10 pages.
- WO 2003/096980 A3 (International Search Report for PCT/US2003/015375), mailed Dec. 3, 2003.

* cited by examiner

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.